Ziftomenib Combos Show Early Safety, Activity in NPM1-Mutant and KMT2A-Rearranged AML

Kura’s menin inhibitor, ziftomenib, for acute myeloid leukemia (AML) was highlighted in OncLive following its latest data readout.

“Ziftomenib demonstrates an encouraging safety and tolerability profile in combination with 7+3 and venetoclax/azacitidine, enabling continuous administration while mitigating the risk of differentiation syndrome,” said the study primary investigator, Amer Zeidan, MBBS, MHS, chief of the Division of Hematologic Malignancies, director of Hematology Early Therapeutics Research at Yale Cancer Center.

Read OncLive’s full coverage and view the press release with the full data below: